Denali Therapeutics Inc.(DNLI) Stock Research - Grey Stern Research

Denali Therapeutics Inc. (DNLI) Stock Analysis

$24.10 (0.04%)

DNLI Financial Performance


Use the table below to view Denali Therapeutics Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q1 - 2024

Metric Value Ranking among Peers
Price $24.10 -
52 Week Low $14.56 -
52 Week High $28.75 -
Market Cap $3.4 Billion 10/22
Gross Margin 0% 11/22
Profit Margin 0% 2/22
EBITDA margin -100% 5/22
Q1 - 2024 Revenue $0 13/22
Q1 - 2024 Earnings -$101.8 Million 17/22
Q1 - 2024 Free Cash Flow -$115.8 Million 16/22
Trailing 4 Quarters Revenue $295.4 Million 5/22
Trailing 4 Quarters Earnings -$137.2 Million 10/22
Quarterly Earnings Growth -15% 9/22
Annual Earnings Growth 64% 1/22
Quarterly Revenue Growth -100% 19/22
Annual Revenue Growth 348% 1/22
Cash On Hand $60.6 Million 17/22
Short Term Debt $7.5 Million 7/22
Long Term Debt $43.0 Million 9/22

Denali Therapeutics Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Denali Therapeutics Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 1/22
PS 11.64 12/22
PB 2.36 14/22
PC 56.74 2/22
Liabilities to Equity 0.09 18/22
ROA -0.09 1/22
ROE -0.09 2/22
Current Ratio 12.59 4/22
Quick Ratio 7.46 8/22
Long Term Debt to Equity 0.03 13/22
Debt to Equity 0.03 15/22
Burn Rate 0.57 18/22
Cash to Cap 0.02 21/22
CCR 1.14 7/22
EV to EBITDA -26.34 14/22
EV to Revenue 11.60 12/22

Company Details

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

CEO: Mr. Ryan Watts

Website: https://www.denalitherapeutics.com

Address: 161 Oyster Point Blvd South San Francisco, CALIFORNIA

Exchange: NASDAQ Global Select

Industry: Biotechnology

Denali Therapeutics Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Denali Therapeutics Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
BeiGene, Ltd. BGNE $16.9 Billion
Blueprint Medicines Corporation BPMC $7.0 Billion
Apellis Pharmaceuticals, Inc. APLS $4.8 Billion
Ascendis Pharma A/S ASND $7.6 Billion
Atreca, Inc. BCEL $3.6 Million
Homology Medicines, Inc. FIXX $3.0 Million
Stoke Therapeutics, Inc. STOK $826.6 Million
Revolution Medicines, Inc. RVMD $7.7 Billion
Black Diamond Therapeutics, Inc. BDTX $348.8 Million
SpringWorks Therapeutics, Inc. SWTX $2.8 Billion
Legend Biotech Corporation LEGN $10.3 Billion
Vaxcyte, Inc. PCVX $9.1 Billion
Avidity Biosciences, Inc. RNA $4.6 Billion
Cerevel Therapeutics Holdings, Inc. CERE $8.1 Billion
Ikena Oncology, Inc. IKNA $82.0 Million
Design Therapeutics, Inc. DSGN $296.6 Million
Werewolf Therapeutics, Inc. HOWL $118.6 Million
Monte Rosa Therapeutics, Inc. GLUE $285.6 Million
Travere Therapeutics, Inc. TVTX $752.9 Million
4D Molecular Therapeutics, Inc. FDMT $948.8 Million
Day One Biopharmaceuticals, Inc. DAWN $1.4 Billion
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
DNLI Income Statements
Quarter Year Revenue Earnings
Q1 2024 $ 0 -$101.8 Million
Q4 2023 $ 0 -$119.5 Million
Q3 2023 $ 1.3 Million -$99.4 Million
Q2 2023 $ 294.1 Million $183.4 Million
Q1 2023 $ 35.1 Million -$88.7 Million
Q4 2022 $ 10.3 Million -$98.7 Million
Q3 2022 $ 3.6 Million -$103.3 Million
Q2 2022 $ 52.5 Million -$58.8 Million

View All

DNLI Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q1 2024 $60.6 Million $1.6 Billion $50.5 Million $1.5 Billion
Q4 2023 $127.1 Million $1.2 Billion $52.2 Million $1.0 Billion
Q3 2023 $148.0 Million $1.2 Billion $53.9 Million $1.1 Billion
Q2 2023 $132.0 Million $1.3 Billion $55.5 Million $1.2 Billion
Q1 2023 $68.1 Million $1.4 Billion $57.1 Million $966.7 Million
Q4 2022 $218.0 Million $1.5 Billion $60.4 Million $1.0 Billion
Q3 2022 $118.6 Million $1.2 Billion $62.0 Million $811.3 Million
Q2 2022 $155.1 Million $1.3 Billion $61.4 Million $884.4 Million

View All

DNLI Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q1 2024 -$115.8 Million -$2.2 Million -$66.5 Million
Q4 2023 -$100.9 Million -$2.2 Million -$20.9 Million
Q3 2023 -$89.4 Million -$2.1 Million $16.0 Million
Q2 2023 -$119.0 Million -$5.9 Million $63.9 Million
Q1 2023 -$61.6 Million -$2.8 Million -$149.9 Million
Q4 2022 -$77.5 Million -$4.8 Million $99.4 Million
Q3 2022 -$63.1 Million -$6.1 Million -$36.5 Million
Q2 2022 -$45.8 Million -$2.9 Million $50.1 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions